Innovent Biologics (HKEX: 01801) has recently received approval for Sycume (teprotumumab biosimilar) to treat thyroid eye disease (TED) in China, making it the country’s first insulin-like growth ...

Report Ocean’s recent report provides an accurate and comprehensive research analysis of the “Saudi Arabia Biosimilars Business and Investment Opportunities Data-book Market ” with a primary focus on ...

They may check for autoantibodies (a sign your immune system is attacking insulin-making cells) or test your urine for ketones, which are often high in type 1 diabetes. If you're pregnant or planning ...

Merida is developing antibody-like therapeutics with the potential to drive deep and durable depletion of pathogenic antibodies, without the broad immunosuppression and resulting toxicities that ...

Merida’s therapies are “antibody-like,” according to its Tuesday announcement, aiming for a “deep and durable depletion” of autoimmune disease-causing autoantibodies without causing broad ...

Methods: A chimeric autoantibody receptor (CAAR) has an autoantigen as the binding domain of the CAR T cell and could allow for specific targeting of autoreactive B cell populations. In Graves’ ...

For treating brain diseases, the bispecific antibodies from Grabody contain a domain designed to bind to insulin-like growth factor 1 receptor (IGF1R), a receptor that transports proteins across ...

By Michael D. Shear Reporting from London Seven pediatric doctors and toxicology experts said on Thursday that jurors were misled by prosecutors who cited unreliable insulin tests during the trial ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...